Your browser version may not work well with NCBI's Web applications. More information here...

Recent Activity

Items 1 - 20 of 101
of 6Next
1:

Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports.

Moore RA, Derry S, McQuay HJ.

Arthritis Res Ther. 2008;10(3):R53. Epub 2008 May 8.

PMID: 18466615 [PubMed - in process]

2:

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports.

Moore RA, Derry S, Makinson GT, McQuay HJ.

Arthritis Res Ther. 2005;7(3):R644-65. Epub 2005 Mar 24. Review. Erratum in: Arthritis Res Ther. 2006;8(1):401.

PMID: 15899051 [PubMed - indexed for MEDLINE]

3:

Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.

Watson DJ, Bolognese JA, Yu C, Krupa D, Curtis S.

Curr Med Res Opin. 2004 Dec;20(12):1899-908.

PMID: 15701208 [PubMed - indexed for MEDLINE]

4:

Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.

Edwards JE, McQuay HJ, Moore RA.

Pain. 2004 Oct;111(3):286-96. Review.

PMID: 15363872 [PubMed - indexed for MEDLINE]

5:

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID: 15099124 [PubMed - indexed for MEDLINE]

6:

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.

Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L; MEDAL Steering Committee.

Lancet. 2006 Nov 18;368(9549):1771-81.

PMID: 17113426 [PubMed - indexed for MEDLINE]

7:

Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.

Curtis SP, Ko AT, Bolognese JA, Cavanaugh PF, Reicin AS.

Curr Med Res Opin. 2006 Dec;22(12):2365-74.

PMID: 17265571 [PubMed - indexed for MEDLINE]

8:

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.

Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.

Am J Gastroenterol. 2003 Aug;98(8):1725-33.

PMID: 12907325 [PubMed - indexed for MEDLINE]

9:

Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials.

Curtis SP, Ng J, Yu Q, Shingo S, Bergman G, McCormick CL, Reicin AS.

Clin Ther. 2004 Jan;26(1):70-83.

PMID: 14996519 [PubMed - indexed for MEDLINE]

10:

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2002;(3):CD001747. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD001747.

PMID: 12137632 [PubMed - indexed for MEDLINE]

11:

Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.

[No authors listed]

Prescrire Int. 2007 Dec;16(92):223-7.

PMID: 18084859 [PubMed - indexed for MEDLINE]

12:

Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. Review.

PMID: 17083854 [PubMed - indexed for MEDLINE]

14:

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD001747.

PMID: 11687119 [PubMed - indexed for MEDLINE]

15:

Selegiline for Alzheimer's disease.

Birks J, Flicker L.

Cochrane Database Syst Rev. 2003;(1):CD000442. Review.

PMID: 12535396 [PubMed - indexed for MEDLINE]

16:

WITHDRAWN: Non-aspirin, non-steroidal anti-inflammatory drugs for treating osteoarthritis of the knee.

Watson M, Brookes ST, Faulkner A, Kirwan J.

Cochrane Database Syst Rev. 2007 Jul 18;(1):CD000142. Review.

PMID: 17636601 [PubMed - indexed for MEDLINE]

17:

Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.

Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, Dixon ME, Polis AB, Mollen AJ, Geba GP; ADVANTAGE Study Group.

Ann Intern Med. 2003 Oct 7;139(7):539-46.

PMID: 14530224 [PubMed - indexed for MEDLINE]

18:

Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis.

Beasley CM Jr, Koke SC, Nilsson ME, Gonzales JS.

Clin Ther. 2000 Nov;22(11):1319-30.

PMID: 11117656 [PubMed - indexed for MEDLINE]

19:

Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).

Krueger K, Lino L, Dore R, Radominski S, Zhang Y, Kaur A, Simpson R, Curtis S.

Ann Rheum Dis. 2008 Mar;67(3):315-22. Epub 2007 Oct 27. Erratum in: Ann Rheum Dis.2008 May;67(5):732.

PMID: 17965424 [PubMed - indexed for MEDLINE]

20:

The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis.

Ramey DR, Watson DJ, Yu C, Bolognese JA, Curtis SP, Reicin AS.

Curr Med Res Opin. 2005 May;21(5):715-22.

PMID: 15974563 [PubMed - indexed for MEDLINE]

Items 1 - 20 of 101
of 6Next